astra: extract claims from 2026-03-01-congress-iss-2032-extension-gap-risk

- Source: inbox/queue/2026-03-01-congress-iss-2032-extension-gap-risk.md
- Domain: space-development
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Astra <PIPELINE>

inbox/archive/health/2026-03-05-petrie-flom-eu-medical-ai-regulation-simplification.md

@@ -7,10 +7,13 @@ date: 2026-03-05
 domain: health
 secondary_domains: [ai-alignment]
 format: policy-analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-04
 priority: high
 tags: [EU-AI-Act, clinical-AI, medical-devices, regulatory-rollback, patient-safety, MDR, IVDR, belief-5, regulatory-capture]
 flagged_for_theseus: ["EU AI Act high-risk classification rollback affects AI safety regulatory landscape globally"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/space-development/2026-03-01-congress-iss-2032-extension-gap-risk.md

@@ -7,9 +7,12 @@ date: 2026-03-01
 domain: space-development
 secondary_domains: []
 format: thread
-status: unprocessed
+status: processed
+processed_by: astra
+processed_date: 2026-04-04
 priority: high
 tags: [ISS, retirement, 2030, 2032, commercial-station, gap-risk, China, Tiangong, governance, Congress]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/queue/2026-03-01-congress-iss-2032-extension-gap-risk.md

@@ -1,60 +0,0 @@
----
-type: source
-title: "Congress pushes ISS extension to 2032; NASA acknowledges post-ISS gap risk; Tiangong would be world's only station"
-author: "Space.com / SpaceNews / NASA"
-url: https://www.space.com/space-exploration/human-spaceflight/congress-wants-the-international-space-station-to-keep-flying-until-2032-heres-why
-date: 2026-03-01
-domain: space-development
-secondary_domains: []
-format: thread
-status: unprocessed
-priority: high
-tags: [ISS, retirement, 2030, 2032, commercial-station, gap-risk, China, Tiangong, governance, Congress]
----
-
-## Content
-
-**Congressional push for ISS extension:**
-A newly advanced NASA Authorization bill pushes ISS retirement from 2030 to September 30, 2032, giving commercial stations an additional 2 years of development time. Senators including Ted Cruz are backing the extension. Primary rationale: commercial station alternatives are "not yet ready" to assume ISS responsibilities by 2030.
-
-**NASA's acknowledgment of gap risk (SpaceNews):**
-Phil McAlister, NASA commercial space division director: "I do not feel like this is a safety risk at all. It is a schedule risk." NASA is supporting multiple companies (Axiom, Blue Origin/Orbital Reef, Voyager/Starlab) to increase probability of on-time delivery and avoid single-provider reliance.
-
-**Gap consequences:**
-- If no commercial replacement by 2030: China's Tiangong would become the world's only inhabited space station — a national security, scientific prestige, and geopolitical concern
-- Continuous human presence in LEO since November 2000 would be interrupted
-- NASA's post-ISS science and commercial programs would have no orbital platform
-
-**CNN (March 21, 2026):** "The end of the ISS is looming, and the US could have a big problem" — framing this as a national security concern, not merely a technical challenge.
-
-**Market context:**
-- Axiom: Building first module, targeting 2027 launch
-- Vast Haven-1: Tested, targeting 2027 launch
-- Starlab: Completed CCDR, transitioning to manufacturing, 2028 Starship-dependent launch
-- Orbital Reef: Only SDR completed (June 2025), furthest behind
-
-None of the commercial stations have announced firm launch dates. ISS 2030 retirement = hard operational deadline.
-
-## Agent Notes
-**Why this matters:** This is the strongest evidence so far that the commercial station market is government-defined, not commercially self-sustaining. Congress extending ISS because commercial stations won't be ready is the inverse of the Phase 2 freeze argument — rather than NASA withholding demand (freeze), Congress is EXTENDING supply (ISS) because demand cannot be self-sustaining without a platform.
-
-**What surprised me:** The Tiangong framing. The US government's concern isn't primarily about commercial revenue for space companies — it's about geopolitical positioning: who has the world's inhabited space station matters to Congress as a national security issue. This reveals that LEO infrastructure is treated as a strategic asset, not a pure commercial market.
-
-**What I expected but didn't find:** A clear legislative path for the ISS 2032 extension. The bill exists (NASA Authorization), but whether it passes and is signed is unclear. The ISS 2030 retirement date is still the operational assumption for most programs.
-
-**KB connections:**
-- [[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]] — Congress extending ISS is governance filling the gap that commercial timelines created
-- [[the 30-year space economy attractor state is a cislunar industrial system with propellant networks lunar ISRU orbital manufacturing and partial life support closure]] — a post-ISS gap weakens this thesis: continuous human presence in LEO is a prerequisite path to the attractor state
-- [[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]] — this case inverts that claim: government maintaining ISS because commercial market isn't ready shows the transition is incomplete
-
-**Extraction hints:**
-1. "The risk of a post-ISS capability gap has elevated commercial space station development to a national security priority, with Congress willing to extend ISS operations to mitigate geopolitical risk of Tiangong becoming the world's only inhabited station" (confidence: likely — evidenced by congressional action and NASA gap acknowledgment)
-2. "No commercial space station has announced a firm launch date as of March 2026, despite ISS 2030 retirement representing a hard operational deadline" (confidence: proven — observable from all available sources)
-3. "Congressional ISS extension proposals reveal that the US government treats low-Earth orbit human presence as a strategic asset requiring government-subsidized continuity, not a pure commercial market" (confidence: experimental — inference from the national security framing)
-
-**Context:** The ISS has been continuously inhabited since November 2000 — 25+ years of human presence. Congress is extending it not because it's technically superior, but because the alternative is a capability gap. This is the most vivid illustration of how government institutions create market demand in space — by maintaining platforms that commercial operators depend on for revenue and experience.
-
-## Curator Notes
-PRIMARY CONNECTION: [[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]
-WHY ARCHIVED: National security framing of LEO presence elevates this beyond commercial economics — government creating demand by maintaining supply (ISS extension), inverting the typical market structure argument; direct evidence for demand threshold concept
-EXTRACTION HINT: The Tiangong-as-only-inhabited-station scenario is the most politically compelling claim candidate — extract with exact temporal framing (if no commercial station by 2030). Also extract the "no firm launch dates" claim as a proven, dated observation. The ISS extension as inversion of the service-buyer transition is the highest-value synthesis claim.

inbox/queue/2026-03-05-petrie-flom-eu-medical-ai-regulation-simplification.md

@@ -1,47 +0,0 @@
----
-type: source
-title: "Simplification or Back to Square One? The Future of EU Medical AI Regulation"
-author: "Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School"
-url: https://petrieflom.law.harvard.edu/2026/03/05/simplification-or-back-to-square-one-the-future-of-eu-medical-ai-regulation/
-date: 2026-03-05
-domain: health
-secondary_domains: [ai-alignment]
-format: policy-analysis
-status: unprocessed
-priority: high
-tags: [EU-AI-Act, clinical-AI, medical-devices, regulatory-rollback, patient-safety, MDR, IVDR, belief-5, regulatory-capture]
-flagged_for_theseus: ["EU AI Act high-risk classification rollback affects AI safety regulatory landscape globally"]
----
-
-## Content
-
-Petrie-Flom Center analysis, March 5, 2026, examining the European Commission's December 2025 proposal to "simplify" medical device and AI regulation in ways that critics argue would remove key safety protections.
-
-**Key developments:**
-- December 2025: European Commission proposed sweeping amendments to MDR/IVDR as part of "simplification" effort, also amending the AI Act.
-- Under the proposal: AI medical devices would still be within scope of the AI Act but would **no longer be subject to the AI Act's high-risk AI system requirements.**
-- The Commission retained the power to adopt delegated/implementing acts to reinstate those requirements — but the default is now non-application.
-- Key concern from Petrie-Flom: "Clinicians will still be expected to use AI safely, interpret outputs, and manage edge cases, yet the regulatory system will no longer guarantee that systems are designed to support meaningful human oversight."
-- Industry lobbied for an even longer delay, citing "dual regulatory burden" as stifling innovation.
-- **WHO explicitly warned of "patient risks due to regulatory vacuum"** (separate Health Policy Watch article).
-- General high-risk AI enforcement: August 2, 2026. Medical devices grace period: August 2027 (16 months later).
-- Grandfathering: Devices placed on market before August 2, 2026 are exempt unless "significant changes in design."
-
-**The core tension:** Industry framing = removing "dual regulatory burden" to enable innovation. Patient safety framing = removing the only external mechanism that would require transparency, human oversight, and bias evaluation for clinical AI.
-
-**US parallel:** FDA simultaneously (January 2026) expanded enforcement discretion for CDS software, with Commissioner Marty Makary framing oversight as something government should "get out of the way" on.
-
-**Convergent signal:** Both EU and US regulatory bodies loosened clinical AI oversight in late 2025 / early 2026, in the same period that research literature accumulated six documented failure modes (NOHARM, demographic bias, automation bias, misinformation propagation, real-world deployment gap, OE corpus mismatch).
-
-## Agent Notes
-**Why this matters:** In Session 9 I identified the regulatory track (EU AI Act, NHS DTAC) as the "gap-closer" between the commercial track (OpenEvidence scaling to 20M consultations/month) and the research track (failure modes accumulating). This paper documents the gap-closer being WEAKENED. The regulatory track is not closing the commercial-research gap; it is being captured and rolled back by commercial pressure.
-**What surprised me:** The simultaneous rollback on BOTH sides of the Atlantic (EU December 2025, FDA January 2026) suggests coordinated industry lobbying or at least a global regulatory capture pattern. The WHO's explicit warning of "patient risks due to regulatory vacuum" is striking — international health authority directly contradicting the regulators rolling back protections.
-**What I expected but didn't find:** Evidence that the EU simplification maintains equivalent safety requirements through a different mechanism. The Petrie-Flom analysis suggests the Commission retained only a power to reinstate requirements, not an obligation — meaning the default is non-application.
-**KB connections:** Belief 5 (clinical AI creates novel safety risks); Session 8 finding that EU AI Act was a "forcing function"; OpenEvidence opacity (already archived); all clinical AI failure mode papers (Sessions 7-9).
-**Extraction hints:** (1) "EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements — shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight"; (2) "Simultaneous regulatory rollback in EU (Dec 2025) and US (Jan 2026) on clinical AI oversight represents coordinated or parallel regulatory capture"; (3) "WHO warning of 'patient risks due to regulatory vacuum' from EU AI Act simplification directly contradicts Commission's deregulatory framing."
-**Context:** Published March 5, 2026 — directly relevant to current regulatory moment. Lords inquiry (April 20, 2026 deadline) and EU AI Act full enforcement (August 2026) are both imminent.
-
-## Curator Notes
-PRIMARY CONNECTION: Clinical AI failure mode papers (Sessions 7-9); EU AI Act enforcement timeline claim
-WHY ARCHIVED: The "regulatory track as gap-closer" framing from Session 9 is now complicated — the regulatory track is being weakened. This is a significant Belief 5 update.
-EXTRACTION HINT: New claim candidate: "Regulatory capture of clinical AI oversight is a sixth institutional failure mode — both EU and FDA simultaneously loosened oversight requirements in late 2025/early 2026 despite accumulating research evidence of five failure modes." Flag as a divergence candidate with existing claims about regulatory track as gap-closer.